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Abstract: A certain number of studies were carried out to address the question of how dysbiosis could
affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal
influence between microbiota composition and immunosuppressive drugs, and how this interaction
may have an impact on the clinical outcome. The aim of this study was to characterize the intestinal
microbiota in a groups of RA patients treatment-naïve, under methotrexate, and/or etanercept (ETN).
Correlations between the gut microbiota composition and validated immunological and clinical
parameters of disease activity were also evaluated. In the current study, a 16S analysis was employed
to explore the gut microbiota of 42 patients affected by RA and 10 healthy controls. Disease activity
score on 28 joints (DAS-28), erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor,
anti-cyclic citrullinated peptides, and dietary and smoking habits were assessed. The composition of
the gut microbiota in RA patients free of therapy is characterized by several abnormalities compared
to healthy controls. Gut dysbiosis in RA patients is associated with different serological and clinical
parameters; in particular, the phylum of Euryarchaeota was directly correlated to DAS and emerged
as an independent risk factor. Patients under treatment with ETN present a partial restoration of a
beneficial microbiota. The results of our study confirm that gut dysbiosis is a hallmark of the disease,
and shows, for the first time, that the anti-tumor necrosis factor alpha (TNF-α) ETN is able to modify
microbial communities, at least partially restoring a beneficial microbiota.
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1. Introduction
The human intestinal microbiota is a complex microcosm composed of more than 1000 different
bacterial species, archaea, fungi, and viruses [1]. There is growing knowledge that these bacteria are
not only involved in the digestion and absorption of food, but they can also exert a protective function
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by preventing adherence of pathogenic bacteria to the mucosal layer, and they play a pivotal role in
modulating the innate and acquired immunity of the host [2–4].
Recent advances in sequencing technologies led to a deep characterization of the human gut
microbiota in healthy subjects. This enabled the investigation of modifications in the structure of gut
commensal communities (called dysbiosis), which could be involved in the onset and maintenance of
different chronic autoimmune diseases, such as inflammatory bowel diseases (IBD) and arthritis [5,6].
Dysbiosis could lead to alterations in the intestinal epithelial cell layer with an increased exposure to
a variety of bacteria and bacterial products leading to a chronic antigenic stimulation, spreading of
inflammatory mediators, and T cell activation [7,8].
It was recently demonstrated that different environmental factors are involved in the development
of both intestinal/oral dysbiosis and arthritis onset and outcome, among which the most relevant are
diet, smoking, infections, and drugs [9–12].
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease of unknown etiology,
potentially leading to progressive joint destruction and disability. In RA patients, an accumulating
body of studies demonstrated a pathogenic role of dysbiosis of the oral microbiota, in particular,
an association between Porphyromonas gingivalis, periodontitis, and the generation of citrullinated
products was clearly demonstrated [13–15].
On the other hand, data regarding the role of intestinal microbiota in these patients
are not conclusive, and no studies address the reciprocal influence between biotechnological
immunosuppressants and microbiota on RA outcome.
Etanercept (ETN, a dimeric recombinant fully human fusion protein consisting of a human 75-kDa
tumor necrosis factor (TNF) receptor linked to the Fc portion of human immunoglobulin G1 (IgG1)) is
one of the five currently available biotechnological agents that target TNF-α. ETN proved to be safe
and effective in reducing disease activity and limiting the progression of joint damage in RA patients;
it can be administered as monotherapy or in combination therapy with methotrexate (MTX) [16].
The aim of this study was to characterize the intestinal microbiota in a group of RA patients
treatment-naïve, under MTX, and/or ETN. Correlations between the gut microbiota composition and
validated immunological and clinical parameters of disease activity were also evaluated.
2. Results
2.1. Microbiota Profile in Rheumatoid Arthritis (RA) Patients Free of Therapy versus Healthy Controls(HCs)
Lifestyle factors, as well as demographic, serologic, and clinical parameters, of the four RA
treatment groups are shown in Table 1.
No significant differences were observed among the RA groups except for the disease duration,
which, as expected, was shorter in the group of naïve and MTX monotherapy patients. HCs were also
similar to RA patients regarding lifestyle factors, but they were significantly younger (p < 0.05).
After passing quality control filters, a mean of 281,218 sequences per sample were obtained.
The assessment of the Shannon index in each sample revealed that α-diversity was neither changed
in naïve patients compared with the HCs, nor in each treatment group (naïve, ETN, MTX, or ETN
plus MTX) relative to patients free of therapy (Figure 1A). Similarly, no significant change in species
richness was observed (Figure 1B).
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Table 1. Main demographic, clinical, and serologic data of the 42 rheumatoid arthritis (RA) patients.
Patient Characteristics Naïve ETN MTX ETN + MTX p-Value
Male n (%) 1 (9) 1 (10) 2 (18) 2 (20) ns
Age 55.7 59.8 62.3 64.6 ns
Varied and balanced diet n (%) 10 (91) 9 (90) 10 (91) 9 (90) ns
Smokers n (%) 1 (9) 3 (30) 1 (9) 1 (10) ns
Disease Duration (years) 6.4 14.8 11.2 19.9
0.007 *
0.07
0.002
0.04
DAS-28 4.3 3.9 4 3.7 ns
RF pos n (%) 8 (73) 6 (60) 8 (73) 6 (60) ns
ACPA pos n (%) 8 (73) 6 (60) 8 (73) 6 (60) ns
ESR (mm/h) 27.4 28.3 22.4 22.6 ns
CRP (mg/L) 5.7 6.5 5.1 6.4 ns
RA = Rheumatoid arthritis; Naïve = patients naïve to immunosuppressants; ETN = etanercept; MTX = methotrexate;
ACPA = anti-citrullinated peptide antibodies; RF = rheumatoid factor; ESR = erythrocyte sedimentation rate; CRP =
C-reactive protein; DAS-28 = disease activity score on 28 joints. Data are expressed as means. * Naïve vs. ETN; naïve vs.
MTX; naïve vs. ETN + MTX; MTX vs. ETN + MTX. ns = not significant.
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Figure 1. Box plots of Shannon diversity index (A) and species richness (B) of microbiota of healthy 
controls and different treatment groups of rheumatoid arthritis (RA) patients. The triangle represents 
the median value. 
As a first approach, we compared the gut microbiota composition of the HCs with that of RA 
patients free of therapy. This analysis revealed that the relative abundance of the microbial phyla 
was almost unchanged (Figure 2A), while significant differences between the two groups were 
found at lower taxonomic levels. The most striking alterations were a five-fold increase in the class 
of Bacilli (Figure 2B) and a seventeen-fold increase in the order of Lactobacillales (Figure 2C) found 
in RA patients with respect to the controls (2.89 ± 3.19 vs. 0.58 ± 0.39; p = 0.035, and 2.69 ± 3.15 vs. 0.15 
± 0.34; p = 0.021, respectively). Significant reductions of the genus Faecalibacterium (12.21 ± 7.4 vs. 
19.72 ± 4.41; p = 0.012) (Figure 3B) and its cognate species Faecalibacterium prausnitzii (3.23 ± 3.22 vs. 
7.97 ± 3.78; p = 0.006) (Figure 3C) were also found. Furthermore, significant changes were also 
observed in the genus Flavobacterium (Figure 3B) and the species Blautia coccoides (Figure 3C), which 
were both represented in the control group, but were not detected at all in RA naïve patients (2 ± 2.44 
vs. 0 ± 0; p = 0.013, and 0.7 ± 0.76 vs. 0 ± 0; p = 0.006). 
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was shown to modify microbiota composition, partly restoring the microbial balance altered by the 
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When compared to naïve patients, major changes were observed in the ETN group. The 
Cyanobacteria significantly increased (0.49 ± 0.5 vs. 0.08 ± 0.07; p = 0.016) (Figure 2A), and the same 
increase was observed in the Nostocophycideae class (Figure 2B) and the Nostocales order (0.35 ± 0.5 
vs. 0 ± 0; p = 0.031) (Figure 2C), which both belong to the phylum of Cyanobacteria. In detail, 
Nostocophycideae and Nostocales, which were not represented among the naïve subjects, were 
instead detected in four out of ten ETN patients. In addition, the class of Deltaproteobacteria (0.07 ± 
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abundance of Enterobateriales (0.07 ± 0.24 vs. 0.85 ± 1.22; p = 0.05) (Figure 2C), while no significant
changes were observed in RA patients upon ETN plus MTX therapy.
2.3. Association of Microbiota Profile with Clinical Pathological Features in RA Patients
Finally, we wondered whether microbiota composition could be associated to clinical parameters
(i.e., sex, age, disease duration, disease activity Score on 28 joints (DAS-28), rheumatoid factor
(RF), anti-cyclic citrullinated peptides antibodies (ACPA), erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) and lifestyle factors (diet and smoking habits) of the RA patients. For this
purpose, correlations were analyzed between microorganisms at each taxonomic level and all the
above described parameters (Figure 4).
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Figure 4. Association of gut icrobiota profile with clinical pathological features in RA patients at the
phylum (A), class (B), order (C), family (D), genus (E), and species (F) levels.
The Spearman correlation analysis revealed a direct association between the male sex
and the abundance of Pasteurellales microbes, while the age of the patients was directly
correlated with Enterobacteriales, Enterobacteriaceae, Flavobacterium, Parabacteroides distasonis,
and Bacteroides ovatus, and inversely correlated to Erysipelotrichi, Coriobacteriales, Erysipelotrichales,
Coriobacteriaceae, Lactobacillaceae, Collinsella, and Collinsella aerofaciens. The disease duration
result was positively associated with the species Bacteroides caccae, while it was negatively
correlated with Parabacteroides merdae. Interestingly, a direct correlation between DAS and
Euryarchaeota, Gammaproteobacteria, Pasteurellales, and Anaerobranca zavarzinii was found,
while Erysipelotrichi, Erysipelotrichales, Coriobacteriales, Coriobacteriaceae, Lactobacillaceae,
Collinsella, Bacteroides rodentium, and Collinsella aerofaciens were inversely associated with
this score. A certain number of correlations were shared by RF and ACPA positivity.
In detail, both factors were positively associated with Roseburia and negatively with Bacilli,
Lactobacillales, and Streptococcus vestibularis. In addition, ACPA positivity was indirectly
correlated with Streptococcaceae, Erysipelotrichaceae, Streptococcus, Bacteroides xylanisolvens,
and Lachnospira pectinoschiza. Direct correlations between ESR and Enterobacteriales, Roseburia faecis,
and Streptococcus parasanguinis, and between CRP and Parabacteroides distasonis emerged from the
analysis. Regarding lifestyle factors, a varied and well-balanced diet was inversely associated with
Pasteurellales, Paraprevotellaceae, Paraprevotella, Blautia, Blautia coccoides, and Bacteroides eggerthi,
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while smoking was positively correlated with Betaproteobacteria, Burkholderiales, Pasteurellales,
Lachnospiraceae, Alcaligenaceae, Roseburia, Lachnospira, Sutterella, Lachnospira pectinoschiza,
Bacteroides denticanum, and Sutterella wadsworthensis.
Additionally, since the variables affecting the microbiota composition in RA are numerous and
can be interconnected, a multivariate approach was followed for a more complete understanding of
these interactions. This analysis revealed that independent factors affecting the disease were DAS and
Euryarchaeota at the phylum level, DAS and Erysipelotrichi at the class level, and only DAS at the
order level. On the contrary, no independent factors were found to correlate with the disease at the
family, genus, and species levels (Supplementary Material).
3. Discussion
In our pilot study, we applied 16S analysis to characterize the gut microbiota of RA patients,
with a particular interest in the effect of synthetic and biotechnological therapies on its composition.
Any significant difference in the Shannon index and in the number of species between healthy and
diseased subjects was observed in our study population. No change was observed in richness and
diversity when patients were classified on the basis of the treatment they received.
A comparison of the gut microbial populations between healthy and affected individuals pointed
out the role of Bacilli in the pathogenesis of RA. Our data are in line with previous studies, in which
the related taxa of Lactobacillaceae and Lactobacillus were significantly more abundant in RA animal
models and patients than in controls. A study by Liu et al. [18] demonstrated that the quantity and
variety of lactobacilli in RA patients was higher than in HCs. A few years later, the same authors
described an increase of the Lactobacillaceae family and the Lactobacillus genus in mice susceptible to
developing collagen-induced arthritis, with respect to mice resistance, thus suggesting these bacteria
as a predisposing factor of the disease [19]. Moreover, Zhang et al. observed an over-representation of
Lactobacillus salivarius in the gut and mouth of RA patients, with the highest levels found in people
most severely affected [12]. Bacilli (especially Lactobacillus) are generally regarded as friendly bacteria
for the host; as such, they are among the most commonly used probiotics. Indeed, the administration
of L. casei and L. delbrueckii was shown to alleviate RA symptoms in experimental models [19–22];
on the other hand, L. rhamnosus GG and L. reuteri administration failed to ameliorate the disease in
patients [23–25] suggesting that different Lactobacillus species may act differently on RA.
The decreased abundance of Faecalibacterium found in our analysis is in agreement with previous
studies carried out on RA [26,27] and other inflammatory conditions [28–30]. The bacteria belonging to
this genus are well-known butyrate producers, help in maintaining the integrity and health of the gut
epithelial barrier, and exhibit anti-inflammatory properties [28–30]; thus, their decrease may contribute
to the onset of an inflammatory status. No previous association of Blautia coccoides (which was depleted
in our naïve group) with RA was reported; nonetheless, it was shown that enriching the gut microbiota
of systemic lupus erythematosus patients with Blautia coccoides, together with Ruminococcus obeum
and Bifidobacterium bifidum, improved the inflammatory status by inducing the production of the
immunosuppressive regulatory T cells (Tregs) [31].
As reported by the latest EULAR recommendations, MTX should be considered the first
immunosuppressive treatment strategy in patients with RA; in the case of an inadequate response,
TNF-α inhibitors or other biotechnological therapies should be started [16]. Zhang et al. previously
reported that MTX can affect microbiota composition, partly reversing disease-related dysbiosis [12].
As of now, data on the effect of microbiota in the outcome of patients receiving immunosuppressive
biotechnological therapies are limited and only refer to IBD patients. For this reason, we next
characterized the gut microbiota of RA patients on different immunosuppressant treatment strategies
(ETN, MTX, or ETN plus MTX) and compared it with that of treatment-naïve patients.
Interestingly, significant changes were found in patients receiving ETN. The phylum of Cyanobacteria
and its cognate Nostocophycideae and Nostocales were enriched in the ETN group. Little is known
about the role of these microorganisms in health and disease; nevertheless, Cyanobacteria produce
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secondary metabolites with multiple bioactivities, including anti-inflammatory and immunosuppressant
activities [32] which may benefit RA patients. Also, the drop in Deltaproteobacteria caused by ETN
could be potentially beneficial if we consider that these microorganisms were found enriched in patients
suffering from ulcerative colitis [33] and that Proteobacteria in general are abundant in both intestinal and
extra-intestinal inflammatory diseases [34]. Moreover, we observed a decrease in Clostridiaceae upon ETN
treatment which could be potentially beneficial since these bacteria were previously found enriched in
patients with RA and IBD-associated arthropathy [35]. In patients treated with MTX, our analysis revealed
a significant decrease in Enterobacteriales, whose lipopolysaccharides may contribute to inflammation [36],
and which were associated with increased intestinal permeability [37], a condition that can be found in
RA patients [38].
The results discussed so far further support the evidence of a link between gut microbiota
and RA, and show, for the first time, that anti-TNF-α therapy can have a beneficial impact on the
microbiota composition.
With the aim of establishing any association between microbial taxa and clinical parameters of
the disease, correlation analyses were performed grouping all forty-two RA patients. Among the most
remarkable results, the pro-inflammatory Gammaproteobacteria and its cognate order of Pasteurellales
displayed a direct correlation with disease activity (DAS-28), while the order of Enterobacteriales
showed a positive association with ESR. Interestingly, the phylum of Euryarchaeota was directly
correlated with DAS and emerged as an independent risk factor in RA when a multivariate analysis
was performed. The function of these microorganisms in humans is still poorly explored, but their
increase was observed in another autoimmune disorder, i.e., multiple sclerosis [39].
A positive association between B. caccae and disease duration was also found. A membrane
protein of B. caccae, namely outer membrane protein W (OmpW), was described as a target of the
immune response associated with IBD. Intriguingly, this protein is structurally related to a protein of
P. gingivalis [40], against which increased autoantibody production was discovered in RA [41].
In addition to the clinical characteristics, some demographic and lifestyle factors of patients were
taken into account. Enterobacteriales and Enterobacteriaceae (belonging to Gammaproteobacteria)
were found to be associated with increasing age, while a number of taxa belonging to
Betaproteobacteria (Alcaligenaceae, Burkholderiales, Sutterella, and S. wadsworthensis) were positively
correlated with the habit of smoking.
When compared to previous reports, this study presents the advantage of having evaluated and
compared, for the first time, the effects induced by synthetic and anti-TNF-α agents, in monotherapy
and combination therapy, on gut dysbiosis in RA patients.
A limit to the current study is that the cross-sectional design can allow us to assess the presence
of gut dysbiosis in RA patients who are treatment-naïve, under ETN, and/or MTX therapy; however,
it does not give information on the predictive value of these changes in relation to RA clinical outcome
and structural progression.
Overall, the current study revealed that RA is characterized by gut dysbiosis, some of which
is associated to the inflammatory status of the disease, suggesting that the microbiota may play an
important role in the promotion and clinical course of RA. Moreover, the partial restoration of a
beneficial microbiota induced mainly by the anti-TNF-α ETN can contribute to the clinical efficacy of
this agent. A deeper understanding of the alterations occurring in the gut microbiota of patients on
different therapeutic regimens could help set up individualized and supportive therapeutic strategies
providing patients with more effective and safe care.
4. Materials and Methods
4.1. Study Population
Forty-two RA patients, according to the European League Against Rheumatism
(EULAR)/American College of Rheumatology (ACR) classification criteria [42] were recruited at the
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outpatient Division of Immunology and Rheumatology, S. Andrea Hospital, Sapienza University
of Rome. Patients were divided into four groups according to current therapy: 11 patients were
naïve to immunosuppressants, 11 patients were receiving MTX, 10 patients were receiving ETN,
and 10 patients were receiving ETN plus MTX. Ten healthy subjects were used as controls (HCs).
The study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki.
An informed consent was obtained by all the patients and the study was approved by the local ethical
Committee (43/2013). All patients were receiving current therapy for at least three months and had to
be naïve to other biotechnological drugs. Steroids and non-steroidal anti-inflammatory drugs (NSAIDs)
had to be stopped at least seven days before the exams.
Any patients or HCs on antibiotics, consuming probiotics, or having a known history of
inflammatory bowel disease or other autoimmune diseases were excluded.
DAS-28, ESR, CRP, RF, ACPA, and dietary and smoking habits were assessed the same day of
stool sample collection.
Patients’ clinical data are described in Table 1.
4.2. Sample Collection and DNA Extraction
Each participant collected a fresh stool sample in a collection tube filled with a DNA stabilization
buffer (Canvax Biotech, Voden Medical Instruments, Meda, Italy). Then, 250 µL of each sample was
processed for microbial DNA extraction using the QIAamp DNA Stool Mini Kit (Qiagen, Milan, Italy)
according to the manufacturer’s protocol. DNA concentration and purity were assessed using a
NanoDrop spectrophotometer (Thermo Scientific, Meda, Italy).
4.3. Next-Generation Sequencing of Bacterial 16S Ribosomal RNA Gene
The Illumina 16S Metagenomic Sequencing Library Preparation instructions were followed
for high-throughput sequencing. Firstly, 12.5 ng of each DNA extract was employed for
the amplification of the V3–V4 hypervariable regions of the bacterial 16S ribosomal RNA
(rRNA) gene, using the following primers with Illumina adapters (underlined): forward primer:
5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG, reverse primer:
5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC, selected
from Klindworth et al. [43]. The amplification reaction was carried out in the presence of the 2× KAPA
HiFi HotStart Ready Mix (Roche, Milan, Italy) under the following conditions: initial denaturation at
95 ◦C for 3 min, followed by 25 cycles of denaturation at 95 ◦C for 30 s, primer annealing at 55 ◦C for
30 s, extension at 72 ◦C for 30 s, with a final elongation at 72 ◦C for 5 min. PCR amplicons were then
purified by means of Agencourt AMPure XP beads (Beckman Coulter, Milan, Italy). The purified DNA
products were then subjected to a further PCR to attach dual Illumina indices (Nextera XT Index Kit,
Illumina Inc., San Diego, CA, USA) necessary for multiplexing. The reaction was performed under the
following conditions: initial denaturation at 95 ◦C for 3 min, followed by eight cycles of denaturation
at 95 ◦C for 30 s, primer annealing at 55 ◦C for 30 s, extension at 72 ◦C for 30 s, with a final elongation at
72 ◦C for 5 min. Following a further PCR purification, the eluted DNA products were quantified using
the Qubit dsDNA BR Kit assay, diluted to a concentration of 4 nM, and pooled in equal proportion
into a single library. Paired-end sequencing (2 × 300 cycles) was carried out on an Illumina MiSeq
device (Illumina Inc.) according to the manufacturer’s instructions. Sequences were demultiplexed
based on index sequences, and FASTQ files were generated.
4.4. Bioinformatic Analysis
Sequence data were analyzed using the 16S Metagenomics App provided by BaseSpace software
(version 1.0.1, Illumina Inc.) which performs taxonomic classification based on the Greengenes database
(available online: http://greengenes.secondgenome.com/downloads/database/13_5). For each
sample, the relative abundance of the top eight taxonomic classifications at each level (from phylum to
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species) was considered for statistical analysis. Moreover, the software calculated the Shannon index
(α-diversity) and the number of species (richness) found in each sample.
4.5. Statistical Analysis
Continuous variables are expressed as means ± standard deviation (SD). Two-group comparisons
were calculated using the Student’s t-test. Correlation analyses were performed using Spearman
rank correlation. Multiple logistic regression analyses with backward variable selection were applied
to assess independent correlates of subject status (healthy/pathological). All statistical tests were
two-tailed and p < 0.05 was considered statistically significant. Statistical analyses were performed by
using the R software, version 3.1.0 (10 April 2014)-B Spring Dance Copyright © 2014 The R Foundation
for Statistical Computing.
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